Delta Lloyd Levensverzekeringen NV disclosed that they hold 1,145,000 shares in the share capital of Galapagos, as of 1 September 2008. This is the first notification Galapagos has received from Delta Lloyd Levensverzekeringen NV. Galapagos had 21,188,829 shares outstanding as of 1 September, 2008.
"We are very pleased to welcome Delta Lloyd as a major institutional shareholder in Galapagos," said Onno van de Stolpe, CEO. "Delta Lloyd is a highly respected investor, and we are proud of their confidence in the long term potential of the Company."
About Galapagos Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis. Its BioFocus DPI division offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs about 500 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com and www.biofocusdpi.com.
CONTACT
Galapagos NV Onno van de Stolpe, CEO Tel: +31 6 2909 8028 ir@glpg.com
